All three receptors for vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells

被引:51
作者
Bairey, O
Boycov, O
Kaganovsky, E
Zimra, Y
Shaklai, M
Rabizadeh, E
机构
[1] Rabin Med Ctr, Inst Hematol, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[4] Rabin Med Ctr, Inst Pathol, IL-49100 Petah Tiqwa, Israel
关键词
chronic lymphocytic leukemia; VEGF; VEGFR-1; VEGFR-2; VEGFR-3; apoptosis; angiogenesis;
D O I
10.1016/S0145-2126(03)00256-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
B-chronic lymphocytic leukemia (B-CLL) cells have a long survival owing to an alteration in the normal pathways of apoptosis. CLL cells have been found to produce and secrete vascular endothelial growth factor (VEGF). In addition to its major role in angiogenesis, VEGF affects cell survival by interfering with apoptosis. The aim of the present study was to investigate the expression of the VEGF receptors VEGFR-1, VEGFR-2, and VEGFR-3 on B-CLL cells, singly and combined. B-CLL cells were isolated from peripheral blood drawn from patients with CLL. Total VEGF receptor, examined in 13 samples by flow cytometery was present in all cases with mean CD19+/VEGF+ expression of 76% (range 52-92%). Specific receptor expression, examined in 27 samples by immunocytochemical methods, was positive for VEGFR- I in all 27 patients and for VEGFR-2 and VEGFR-3 in 26 (96%). These findings suggest that the VEGF transduction pathway may be very active in CLL cells, and both its paracrine and autocrine pathways may contribute to their enhanced survival. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:243 / 248
页数:6
相关论文
共 26 条
  • [1] Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL)
    Aguayo, A
    Manshouri, T
    O'Brien, S
    Keating, M
    Beran, M
    Koller, C
    Kantarjian, H
    Rogers, A
    Albitar, M
    [J]. LEUKEMIA RESEARCH, 2001, 25 (04) : 279 - 285
  • [2] Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia
    Bairey, O
    Zimra, Y
    Shaklai, M
    Rabizadeh, E
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (02) : 400 - 406
  • [3] EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR AND ITS RECEPTORS FLT AND KDR IN OVARIAN-CARCINOMA
    BOOCOCK, CA
    CHARNOCKJONES, DS
    SHARKEY, AM
    MCLAREN, J
    BARKER, PJ
    WRIGHT, KA
    TWENTYMAN, PR
    SMITH, SK
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (07): : 506 - 516
  • [4] Carroll RS, 1999, CANCER-AM CANCER SOC, V86, P1335, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1335::AID-CNCR32>3.0.CO
  • [5] 2-Z
  • [6] Chen HJ, 2000, BLOOD, V96, P3181
  • [7] National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
    Cheson, BD
    Bennett, JM
    Grever, M
    Kay, N
    Keating, MJ
    OBrien, S
    Rai, KR
    [J]. BLOOD, 1996, 87 (12) : 4990 - 4997
  • [8] Molecular biology of the VEGF and the VEGF receptor family
    Clauss, M
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2000, 26 (05) : 561 - 569
  • [9] De Jong JS, 1998, J PATHOL, V184, P44
  • [10] Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
    Dias, S
    Hattori, K
    Heissig, B
    Zhu, ZP
    Wu, Y
    Witte, L
    Hicklin, DJ
    Tateno, M
    Bohlen, P
    Moore, MAS
    Rafii, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10857 - 10862